TRLV Stock Forecast & Price Target

Trulieve Cannabis is viewed favorably because its vertically integrated, federally compliant medical platform combines scale, automation, and strong patient engagement, with 206 DEA-registered dispensaries, 3.5M sq. ft. of cultivation and production capacity, and 1Q26 medical customer retention of 78%. Its Florida core remains highly productive, with 169 dispensaries, flower sales 56% above the state average, oil volumes more than 2x the next-largest competitor, and 2Q26 EBITDA of $98M on $271M of revenue, while GA and PA are helping offset seasonality. Additional upside comes from embedded catalysts that are not reflected in current estimates, including Texas final license approval, expanded GA access, and potential adult-use rescheduling that could benefit its retained 90% interest in Harvest.

Trulieve Cannabis is exposed to structurally weak fundamentals because Florida, its most important market, typically sees a 3Q revenue lull as snowbirds leave during warmer months, while the company also faces intense competition and pricing pressure in mature markets like Florida and Arizona. Its growth case depends on delayed regulatory progress, including final approval of its Texas license and possible adult-use cannabis rescheduling, yet prior to rescheduling there was no federal registration pathway and Section 280E continued to block ordinary expense deductions such as payroll, rent, marketing, and utilities. In addition, restrictive state programs like Alabama’s and slower-than-expected expansion across state-level markets could limit earnings growth, constrain margins, and reduce the value of its expansion optionality.